sacituzumab govitecan
gilead sciences
['neostar', 'tnbc', 'sacituzumab', 'brca']
dr. rebecca dent presents the first results of the neostar trial, testing neoadjuvant sacituzumab govitecan in patients with etnbc (l.spring et al). pcr rate was 30%, with a signal of improved benefit in gbrcamut patients (pcr rate 75%).
#asco22 
Paolo Tarantino, MD, (@PTarantinoMD) #BCSM Researcher from @IEOufficiale, takes over our Twitter today to discuss #ASCO22.